Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Kenna R. Mills Shaw, Debu Tripathy, Senthil Damodaran, Funda Meric-Bernstam, Mehmet Esat Demirhan, Aysegul A. Sahin, Filip Janku, Xiaofeng Zheng, Agda Karina Eterovic, Lauren Brusco, Tae-Beom Kim, Ken Chen, Maryam Shariati, John Mendelsohn, Reva K. Basho, Gordon B. Mills, Jordi Rodon, Naoto T. Ueno, Russell Broaddus, Chetna Wathoo, Coya Tapia
Publikováno v:
JCO Precision Oncology. :1-15
Purpose To determine the significant genomic alterations in patients with metastatic breast cancer (MBC) and survival outcomes in common genotypes. Patients and Methods High-depth next-generation sequencing was performed for 202 genes in tumor and no
Autor:
Lajos Pusztai, Hannah Dzimitrowicz, Vicente Valero, Debu Tripathy, Akshara Singareeka Raghavendra, Michael Berger, Rashmi Krishna Murthy, Annette Hood, Christos Hatzis, Craig A. Vargo, Osama Abdelghany
Publikováno v:
Journal of Clinical Oncology. 34:3511-3517
Purpose Ado-trastuzumab emtansine (T-DM1) is currently approved for treatment in patients with human epidermal growth factor receptor 2 (HER2)–positive, metastatic breast cancer (MBC) who previously received trastuzumab and a taxane. However, there
Autor:
Scott S. Tykodi, Debu Tripathy, Jianjun Gao, Daniel C. Cho, Arlene O. Siefker-Radtke, Mario Sznol, Sara M. Tolaney, Giovanni Grignani, Nizar M. Tannir, Igor Puzanov, Vassiliki A. Papadimitrakopoulou, Scott N. Gettinger, Wendy L. Clemens, Brendan D. Curti, Michael E. Hurwitz, Adi Diab, James Larkin, Mary Ann Tagliaferri, Nuhad K. Ibrahim, Harriet M. Kluger
Publikováno v:
Journal of Clinical Oncology. 36:3006-3006
3006Background: PIVOT is an ongoing, open-label, phase 1/2 study of NKTR-214 (214; CD122-biased agonist) plus PD-1 inhibitor nivolumab (N) in patients (pts) with advanced cancers (MEL, RCC, NSCLC, TNBC, and UC). 214 monotherapy increases newly prolif
Autor:
Sunil Badve, Gabriel N. Hortobagyi, Laura A. Knight, Andrew K. Godwin, Daniel F. Hayes, Hannah M. Linden, William E. Barlow, Richard D. Kennedy, Yesim Gökmen-Polar, Priyanka Sharma, Debu Tripathy, Harsh B. Pathak, Kamilla Isakova, Steven Walker
Publikováno v:
Journal of Clinical Oncology. 35:529-529
529 Background: Biomarkers of response and resistance to adjuvant chemotherapy for TNBC are needed. Deficiency in DNA damage response (DDR) and repair pathways have been reported in TNBC and may impact response to chemotherapy. Aims: To investigate D
Autor:
Teresita Vega, Vicente Valero, Debu Tripathy, Akshara Singareeka Raghavendra, Rashmi Krishna Murthy, Yao Wong, Javier Perez Irizarry, Mariana Chavez-Mac Gregor, Carlos H. Barcenas, Lajos Pusztai, Christos Hatzis
Publikováno v:
Journal of Clinical Oncology. 35:1021-1021
1021 Background: An increasing number of metastatic HER2 positive cancers represent de novo stage IV disease as fewer early stage patients relapse. We hypothesize that a subset of these has long progression free survival (PFS) after initial combined
Autor:
Caroline Bumb, Melody A. Cobleigh, Ron Bose, Rachel A. Freedman, Philippe L. Bedard, Debu Tripathy, Hussam Al-Kateb, Matthew P. Goetz, Andres Forero, Timothy J. Pluard, Polly A. Niravath, Daniel F. Hayes, Christy A. Russell, Carey K. Anders, Matthew J. Ellis, Feng Gao, Mark D. Pegram, Cynthia X. Ma, Michael Naughton, Kimberly L. Blackwell
Publikováno v:
Journal of Clinical Oncology. 34:516-516
516Background: HER2 mutation occurs in ~2% of breast cancer (BC). Preclinical models suggested neratinib, an irreversible HER2/EGFR tyrosine kinase inhibitor, could be an effective treatment. This trial was conducted to assess the clinical benefit ra
Autor:
Naoto T. Ueno, Jie Willey, Rashmi Krishna Murthy, Ricardo H. Alvarez, S. Jackson, Debu Tripathy, Sharon H. Giordano, Stacy L. Moulder, Carlos H. Barcenas, Abenaa M. Brewster, Nuhad K. Ibrahim, Vicente Valero, Ronald S. Walters, Daniel J. Booser, Powel H. Brown, Jangsoon Lee, Meghan Sri Karuturi, Bora Lim
Publikováno v:
Journal of Clinical Oncology. 34:609-609
609Background: Entinostat (E) an HDAC inhibitor, and Lapatinib (L) given in combination induces FOXO3a and mediates Bim1 expression in HER2+ cell lines resulting in apoptosis [Lee et al. BCRT 2014]...